4.7 Article

Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease

期刊

EUROPEAN HEART JOURNAL
卷 43, 期 1, 页码 56-+

出版社

OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehab441

关键词

All-cause death; Coronary artery bypass grafting; Diabetes; Percutaneous coronary intervention; SYNTAX

资金

  1. German Foundation of Heart Research (Frankfurt am Main, Germany)
  2. Boston Scientific Corporation (Marlborough, MA, USA)
  3. Science Foundation Research Professorship Award [15/RP/2765]

向作者/读者索取更多资源

This study compared the 10-year all-cause death rates in patients with three-vessel disease or left main coronary artery disease who underwent either PCI or CABG. The results showed no significant difference in all-cause death rates at 10 years between PCI and CABG, regardless of diabetic status. However, there might be a survival benefit with CABG in patients with insulin-treated diabetes.
Aims The aim of this article was to compare rates of all-cause death at 10 years following coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in patients with or without diabetes. Methods and results The SYNTAXES study evaluated up to 10-year survival of 1800 patients with three-vessel disease (3VD) and/or left main coronary artery disease (LMCAD) randomized to receive either PCI or CABG in the SYNTAX trial. Ten-year all-cause death according to diabetic status and revascularization strategy was examined. In diabetics (n = 452), the risk of mortality was numerically higher with PCI compared with CABG at 5 years [19.6% vs. 13.3%, hazard ratio (HR): 1.53, 95% confidence interval (CI): 0.96, 2.43, P = 0.075], with the opposite seen between 5 and 10 years (PCI vs. CABG: 20.8% vs. 24.4%, HR: 0.82, 95% CI: 0.52, 1.27, P = 0.366). Irrespective of diabetic status, there was no significant difference in all-cause death at 10 years between patients receiving PCI or CABG, the absolute treatment difference was 1.9% in diabetics (PCI vs. CABG: 36.4% vs. 34.5%, difference: 1.9%, 95% CI: -7.6%, 11.1%, P = 0.551). Among insulin-treated patients (n = 182), all-cause death at 10 years was numerically higher with PCI (47.9% vs. 39.6%, difference: 8.2%, 95% CI: -6.5%, 22.5%, P = 0.227). Conclusions The treatment effects of PCI vs. CABG on all-cause death at 10 years in patients with 3VD and/or LMCAD were similar irrespective of the presence of diabetes. There may, however, be a survival benefit with CABG in patients with insulin-treated diabetes. The association between revascularization strategy and very long-term ischaemic and safety outcomes for patients with diabetes needs further investigation in dedicated trials.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据